Buy Biogen | NASDAQ – BIIB | Short Term Trading Advice | Biotechnology Sector | 3th Dec 2025 | Expected Gain 5% – 6%

Date

3 December 2025

Analysed By

Naranj Capital Research Desk

Stock Market

NASDAQ, United States of America

Stock Trading Advice in USA

Buy

Buy
Range

Target

Stoploss

Upside
Potential

Trade
Duration

Biogen

178 - 180

188 - 190

Below 180

5-6%

12 - 14 Days

Buy Biogen

Buy
Range 178 - 180

Target 188 - 190

Stoploss Below 180

Upside
Potential 5-6%

Trade
Duration 12 - 14 Days

* Once the first target hit, reset the StopLoss at your buying price.

* Trade durations are approximate; actual holding period may vary.

Biogen (NASDAQ: BIIB) - Stock Overview

NASDAQ Code

Stock Name

Sector

52 Weeks High

52 Weeks Low

BIIB

Biogen

Biotechnology

185.17

110.04

NASDAQ Code BIIB

Stock Name Biogen

Sector Biotechnology

52 Weeks High 185.17

52 Weeks Low 110.04

Company profile

Biogen Inc. is a biotechnology company that develops and delivers treatments for neurological and neurodegenerative diseases. Its key products include therapies for multiple sclerosis, spinal muscular atrophy, ALS, Friedreich’s Ataxia, and several biosimilars for conditions like arthritis and cancer. Biogen also collaborates with major partners such as Eisai, Genentech, Ionis, and Sage Therapeutics to develop new drugs in areas like Alzheimer’s, Parkinson’s, and other brain disorders. Founded in 1978, the company is headquartered in Cambridge, Massachusetts.

Biogen (NASDAQ: BIIB) - Q3 FY25 Financials Highlights

Metric	Q3 2025	Q2 2025	Change (QoQ)	Q3 2024	Change (YoY)
Total Revenue	$2.535B	$2.646B	-4.2%	$2.466B	+2.8%
GAAP Diluted EPS	$3.17	$4.33	-26.8%	$2.66	+19.2%
Non-GAAP Diluted EPS	$4.81	$5.47	-12.1%	$4.08	+17.9%
Free Cash Flow	$1.226B	$0.134B	+814.9%	$0.901B	+36.1%
Launch Products Revenue	$257M	$291M	-11.7%	$153.8M	+67.0%
MS Franchise Revenue	$1.062B	$1.107B	-4.1%	$1.052B	+0.9%

Biogen (NASDAQ: BIIB) - Earnings Call Summary for Q3/2025

Strong Beat: Biogen topped expectations with $2.53B revenue (+3% YoY) and Non-GAAP EPS of $4.81 (+18%), helped by cost control and strong new product sales.
New Products Growing Fast: Launch products brought in $257M (+67% YoY).
- Leqembi: ~$121M sales (+82%)
- Skyclarys: ~$133M sales (+30%)
Stable Core Business: The MS segment grew 1%, supported by strong Vumerity demand and pricing benefits, offsetting declines in older drugs.
Improved Guidance: Biogen now expects FY25 revenue to be flat to +1%, but EPS trimmed to $14.50–$15.00 due to higher R&D spending.

Biogen (NASDAQ: BIIB) vs NASDAQ - Relative Performance

The image showcases Biogen's 1-year performance relative to NASDAQ. — Relative Performance - Last 1 Year
BIIB — NASDAQ —

Biogen (NASDAQ: BIIB) - Price Performance

Biogen (NASDAQ: BIIB) - Technical Analysis (Daily)

After a prolonged consolidation, the stock has formed an inverted head & shoulders pattern.
With a breakout above the neckline, the price is showing strong bullish momentum and is likely to continue its upward move.